Medipost, Inc.
Quick facts
Phase 3 pipeline
- CARTISTEM® + Debridement · Orthopedics / Regenerative Medicine
CARTISTEM is an allogeneic bone marrow-derived mesenchymal stem cell product that regenerates damaged cartilage tissue when combined with surgical debridement.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Medipost, Inc.
What is Medipost, Inc.'s pipeline?
Medipost, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include CARTISTEM® + Debridement.
Related
- Sector hub: All tracked pharma companies